NEW YORK, NY / ACCESSWIRE / September 15, 2021 / Innodata Inc. (NASDAQ:INOD), a leading data engineering company, today announced it has expanded its AI data annotation capabilities to include patient medical records and has won a contract with a new customer, a Fortune 500 insurance company, to support its medical record predictive model development and business analytics. Innodata anticipates revenue from the engagement will be approximately $3 million one-time and approximately $800 thousand per year ongoing.

By synthesizing capabilities from its AI data annotation platform and Synodex medical data extraction platform, Innodata has created a medical record AI data annotation platform that can create large volumes of high-quality AI training data, is fully HIPAA-compliant, meets stringent information security protocols, and leverages auto-tagging intelligence with Innodata's proprietary AI models.

AI-related spend in the global healthcare market is expected to reach $62 billion by 2027, up from $3 billion this year.[1] Analysts expect AI to be applied to areas like diagnostics, risk analytics, precision medicine, administrative processes within provider and payer organizations, and drug discovery. Major factors driving this growth include the increasing volume of healthcare data, the growing complexity of datasets, the need to reduce healthcare costs, and the recent AI adoption by pharmaceutical and biotechnology companies to expedite COVID-19 vaccine and drug development.

"As AI moves from a 'nice-to-have' to a 'must-have', healthcare, insurance, and life sciences companies are likely to confront the data challenges most often cited as impeding AI success," said Jack Abuhoff, Chief Executive Officer at Innodata. "Innodata is well-positioned to help these companies successfully overcome their data challenges and scale their use of AI."

Learn more about Innodata's healthcare solutions here and Innodata's insurance solutions here.

About Innodata

Innodata (NASDAQ:INOD) is a leading data engineering company. Prestigious companies across the globe turn to Innodata for help with their biggest data challenges. By combining advanced machine learning and artificial intelligence (ML/AI) technologies, a global workforce of over 3,500 subject matter experts, and a high-security infrastructure, we're helping usher in the promise of digital data and ubiquitous AI. Visit www.innodata.com to learn more.

Forward Looking Statements

This press release may contain forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. Words such as "project," "believe," "expect," "can," "continue," "could," "intend," "may," "should," "will," "anticipate," "indicate," "forecast," "predict," "likely," "goals," "estimate," "plan," "potential," or the negatives thereof and other similar expressions generally identify forward-looking statements, which speak only as of the date hereof.

These forward-looking statements are based on management's current expectations, assumptions and estimates and are subject to a number of risks and uncertainties, including without limitation, the expected or potential effects of the novel coronavirus (COVID-19) pandemic and the responses of governments, the general global population, our customers, and the Company thereto; that contracts may be terminated by clients; projected or committed volumes of work may not materialize; continuing Digital Data Solutions segment reliance on project-based work and the primarily at-will nature of such contracts and the ability of these clients to reduce, delay or cancel projects; the likelihood of continued development of the markets, particularly new and emerging markets, that our services support; continuing Digital Data Solutions segment revenue concentration in a limited number of clients; potential inability to replace projects that are completed, canceled or reduced; our dependency on content providers in our Agility segment; difficulty in integrating and deriving synergies from acquisitions, joint venture and strategic investments; potential undiscovered liabilities of companies and businesses that we may acquire; potential impairment of the carrying value of goodwill and other acquired intangible assets of companies and businesses that we acquire; changes in our business or growth strategy; a continued downturn in or depressed market conditions, whether as a result of the COVID-19 pandemic or otherwise; changes in external market factors; the ability and willingness of our clients and prospective clients to execute business plans that give rise to requirements for our services; changes in our business or growth strategy; the emergence of new or growth in existing competitors; various other competitive and technological factors; our use of and reliance on information technology systems, including potential security breaches, cyber-attacks, privacy breaches or data breaches that result in the unauthorized disclosure of consumer, client, employee or Company information, or service interruptions; and other risks and uncertainties indicated from time to time in our filings with the Securities and Exchange Commission.

Our actual results could differ materially from the results referred to in forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, uncertainty around the COVID-19 pandemic and the effects of the global response thereto and the risks discussed in Part I, Item 1A. "Risk Factors," Part II, Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations, and other parts of our Annual Report on Form 10-K, filed with the Securities and Exchange Commission on March 15, 2021, as updated or amended by our other filings with the Securities and Exchange Commission. In light of these risks and uncertainties, there can be no assurance that the results referred to in the forward-looking statements will occur, and you should not place undue reliance on these forward-looking statements. We undertake no obligation to update or review any guidance or other forward-looking statements, whether as a result of new information, future developments or otherwise, except as may be required by the Federal securities laws

View source version on accesswire.com:
https://www.accesswire.com/664057/Innodata-Announces-New-AI-Data-Annotation-Capabilities-for-Patient-Medical-Records-and-Significant-New-Customer-Acquisition